Ga DOTA

Phase 1Small molecule

UUniversity of California, Davis

Ga DOTA is one of 57 small molecule programs targeting Metastatic Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic CancerRecruiting

Metastatic Pancreatic CancerActive, not recruiting

Lobular Breast CarcinomaRecruiting

TEDRecruiting

Metastatic CancerPhase 1

Recruiting

Metastatic Pancreatic CancerPhase 1

Active, not recruiting

Lobular Breast CarcinomaPhase 1

Recruiting

TEDPhase 1

Recruiting

Competition

Competitive Landscape

45 competitors in TED

#DrugCompanyPhaseTrials

Farxiga

AstraZeneca

Approved

2 2

Scemblix

Novartis

Approved

1 3

Alecensa

Roche

Approved

1 4

Calquence

AstraZeneca

Phase 3

2 5

Rituxan

Roche

Phase 3

2 6

Medrol

Pfizer

Phase 3

2 7

Golytely

Bayer

Phase 3

1 8

Treanda

AAzurity Pharmaceuticals

Phase 3

1 9

Fludara

Sanofi

Phase 2

3 10

Eliquis

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

TED

NCT06228482

Q2 2027

Phase 1Recruiting

Lobular Breast Carcinoma

NCT07020806

Q4 2027

Phase 1Active, not recruiting

Metastatic Pancreatic Cancer

NCT04665947

Q4 2029

Phase 1Recruiting

Metastatic Cancer

NCT06389123

Clinical

Trials by Indication[1]

TED1 trial

Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6

Recruiting·UUniversity of California, Davis·Phase 1·NCT06228482·40 enrolled

Lobular Breast Carcinoma1 trial

[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)

Recruiting·UUniversity of California, Davis·Phase 1·NCT07020806·30 enrolled

Metastatic Pancreatic Cancer1 trial

First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer

Active, not recruiting·UUniversity of California, Davis·Phase 1·NCT04665947·30 enrolled

Metastatic Cancer1 trial

A Novel Molecularly Targeted Theranostic Approach Via the αvβ6 Integrin for the Detection and Treatment of Metastatic Carcinomas

Recruiting·UUniversity of California, Davis·Phase 1·NCT06389123·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Ga DOTA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ga DOTA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ga DOTA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, Davis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of California, Davis

Ga DOTA

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q4 2027

Q4 2029

Trials by Indication[1]

TED1 trial

Lobular Breast Carcinoma1 trial

Metastatic Pancreatic Cancer1 trial

Metastatic Cancer1 trial

References

Drug Info

Quick Facts

Related News